Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Bota Bio Adds $100 Million to B Round for Synthetic Biotech Manufacturing

publication date: Jul 29, 2021

Bota Bio, a San Francisco-Hangzhou industrial synthetic biotech company, added $100 million to its Series B round. Bota uses biological systems for clean and efficient bio-manufacturing of common household and industrial products. It points out current manufacturing methods cause environmental damage. Bota, whose pipeline includes consumer goods, food, nutrition and pharmaceutical products, wants to promote a sustainable biologic manufacturing processes. The financing was led by Sequoia Capital China. More details...

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China